Defender Capital, LLC. - LINEAGE CELL THERAPEUTICS IN ownership

LINEAGE CELL THERAPEUTICS IN's ticker is LCTX and the CUSIP is 53566P109. A total of 115 filers reported holding LINEAGE CELL THERAPEUTICS IN in Q2 2021. The put-call ratio across all filers is 0.65 and the average weighting 0.1%.

Quarter-by-quarter ownership
Defender Capital, LLC. ownership history of LINEAGE CELL THERAPEUTICS IN
ValueSharesWeighting
Q3 2023$6,117,722
-15.1%
5,184,510
+1.5%
2.22%
-10.6%
Q2 2023$7,204,214
-6.5%
5,109,710
-0.5%
2.48%
-7.9%
Q1 2023$7,704,128
+29.3%
5,136,085
+0.8%
2.69%
+11.7%
Q4 2022$5,959,436
+1.7%
5,093,535
-1.7%
2.41%
+4.9%
Q3 2022$5,862,000
-27.7%
5,184,035
+1.0%
2.30%
-27.8%
Q2 2022$8,108,000
+1.6%
5,131,935
+2.5%
3.18%
+14.6%
Q1 2022$7,983,000
-34.8%
5,006,185
+0.2%
2.78%
-29.3%
Q4 2021$12,245,000
-3.6%
4,997,870
+4.2%
3.92%
-5.0%
Q3 2021$12,707,000
-11.5%
4,798,270
-4.7%
4.13%
-13.3%
Q2 2021$14,354,000
+23.5%
5,036,720
+1.7%
4.77%
+15.1%
Q1 2021$11,618,000
+39.4%
4,950,720
+4.5%
4.14%
+14.2%
Q4 2020$8,335,000
+76.3%
4,735,990
-6.2%
3.63%
+55.8%
Q3 2020$4,729,000
+17.0%
5,048,990
+8.7%
2.33%
-2.3%
Q2 2020$4,042,000
+10.5%
4,646,290
+5.2%
2.38%
-10.7%
Q1 2020$3,657,000
+3.3%
4,416,590
+11.1%
2.67%
-15.0%
Q4 2019$3,540,000
-4.6%
3,977,045
+4.8%
3.14%
-4.5%
Q3 2019$3,709,0003,794,0453.29%
Other shareholders
LINEAGE CELL THERAPEUTICS IN shareholders Q2 2021
NameSharesValueWeighting ↓
BROADWOOD CAPITAL INC 34,935,485$55,198,0004.16%
Raffles Associates 1,930,536$3,050,0003.32%
Defender Capital, LLC. 5,131,935$8,108,0003.18%
Prescott General Partners LLC 1,851,851$2,926,0000.20%
DAFNA Capital Management LLC 140,000$221,0000.06%
Laurion Capital Management LP 2,422,367$3,827,0000.06%
Beirne Wealth Consulting Services, LLC 45,000$71,0000.05%
Fort Sheridan Advisors LLC 78,931$125,0000.04%
Long Focus Capital Management, LLC 215,000$340,0000.04%
MORGAN JESS S & CO INC 20,000$32,0000.03%
View complete list of LINEAGE CELL THERAPEUTICS IN shareholders